AstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EU
By Christian Moess Laursen
AstraZeneca said its lung-cancer drug Enhertu has been recommended for approval in the European Union following positive test results.
The Anglo-Swedish pharma giant said Friday that Enhertu showed an objective response rate of 49.0% and a median duration of response of 16.8 months. In addition, the tests showed a disease control rate of 93.1%.
The drug has been recommended for approval as a monotherapy for the treatment of adult patients with advanced non-small-cell lung cancer whose tumors have an activating HER2 mutation.
This form of lung cancer is an aggressive type that often affects younger patients and has a poor prognosis, with limited approved therapies.
"This milestone recognizes the unmet need in the EU and if approved, Enhertu will provide the first targeted treatment option for these patients," Executive Vice President Susan Galbraith said.
Enhertu is being jointly developed and commercialized with Japan's Daiichi Sankyo.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
September 15, 2023 10:36 ET (14:36 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom